Optimizing Oncology Tennr Workflows with Intelligent Automation

In oncology, where treatment urgency is paramount, optimizing **oncology tennr** workflows — those reliant on faxes and paper forms — is critical for timely patient care.

Revenue cycle leaders and prior authorization coordinators in cancer care face immense pressure to secure approvals for high-cost therapies and complex regimens. Traditional, manual processes, often involving fax and paper, introduce delays and administrative burden, directly impacting patient access to life-saving treatments. Klivira transforms these workflows, moving beyond basic automation to deliver intelligent, integrated prior authorization for oncology.

The Unique Complexity of Oncology Prior Authorization

Oncology prior authorization is among the most intricate in healthcare, characterized by high-cost biologics, infusion therapies, radiation oncology, and frequent regimen changes. The sheer volume of PA events per patient—often exceeding 10–20 over a treatment course—demands a robust, automated solution to prevent delays that can impact patient outcomes.

High-Volume PA Triggers in Cancer Care

J-code chemotherapy and biologic infusions, including immunotherapies and antibody-drug conjugates.
Advanced imaging for staging and surveillance, such as PET/CT and tumor-specific molecular imaging.
Radiation oncology procedures, including IMRT, IGRT, SBRT, and proton-beam therapy.
Genetic and molecular testing (NGS panels, single-gene tests) for treatment selection.
Supportive care medications like growth factors (G-CSF, ESAs) and bone-targeting agents.

Moving Beyond Basic Fax & Paper Automation in Oncology

Many oncology practices still grapple with "Tennr-like" workflows, where prior authorization requests and supporting documentation are heavily reliant on faxes and paper forms. While basic automation can digitize these inputs, it often lacks the clinical intelligence and deep integration required to truly streamline oncology PA, leading to documentation gaps and delays.

Critical Documentation & Common Denial Reasons

Diagnosis confirmation (pathology, AJCC TNM staging, molecular markers like ER/PR/HER2, EGFR/ALK/PD-L1).
Prior-line treatment response and rationale for new regimens.
Performance status (ECOG/Karnofsky) and relevant comorbidities.
NCCN Clinical Practice Guidelines and NCCN Drugs & Biologics Compendium citations for off-label use.
Common denials: off-label use without compendium support, step therapy requirements, documentation gaps, and site-of-service mismatches.

Klivira's Intelligent Automation for Oncology PA

Klivira's platform provides a comprehensive solution for oncology prior authorization, integrating directly with EMRs to capture clinical data and connect with payer portals. This approach automates the submission process, validates against NCCN guidelines, and proactively identifies potential denial risks, significantly reducing the administrative burden.

Klivira's Specialty-Specific Capabilities

NCCN-compendium-aware policy logic that surfaces required documentation per regimen and tumor type.
Regimen-level PA workflow that bundles related components (chemo + targeted + biologic) for efficient submission.
Medical-vs-pharmacy benefit routing to manage the split between IV and oral oncology drugs (X12 278 vs. ePA/NCPDP SCRIPT).
Concurrent PA tracking for the dozens of PA events per patient across the entire treatment course.
Peer-to-peer scheduling integration to streamline clinical-necessity denial reviews.

Frequently asked questions

How does Klivira handle the urgency of oncology treatment initiation?

Klivira's automation platform is designed to accelerate the prior authorization process by reducing manual tasks and proactive identification of documentation requirements. By integrating with EMRs and payer portals, we aim to minimize PA cycle times, helping to ensure that cancer patients receive timely access to critical treatments.

Can Klivira manage both medical and pharmacy benefit prior authorizations for oncology drugs?

Yes, Klivira's platform is built to manage the complex split between medical and pharmacy benefit oncology drugs. We route medical benefit PAs (J-codes) via X12 278 or payer portals, and pharmacy benefit PAs (oral oncolytics) through ePA channels like CoverMyMeds and Surescripts, ensuring complete coverage.

How does Klivira address the frequent regimen changes common in oncology?

Klivira supports regimen-level PA workflows and concurrent tracking for multiple PA events per patient. This means our system is designed to adapt to regimen modifications due to toxicity or progression, initiating new PA cycles efficiently and maintaining a comprehensive view of all active authorizations.

What role do NCCN guidelines play in Klivira's oncology PA automation?

Klivira incorporates NCCN-compendium-aware policy logic directly into the PA workflow. This allows our platform to surface required documentation based on specific regimens and tumor types, align submissions with accepted medical necessity criteria, and proactively flag potential issues related to off-label use.

How does Klivira improve upon traditional "Tennr-like" fax-based PA processes?

Klivira moves beyond basic digitization of faxes by offering intelligent, end-to-end prior authorization automation. We integrate clinical data directly from your EMR, apply payer-specific rules and clinical guidelines, and submit requests electronically, eliminating the manual data entry, routing, and follow-up inherent in traditional fax and paper workflows.